IP Library Granted Patent US 9,274,110
Granted Patent B2
US 9,274,110 · App. 14/123,699 · Granted Mar 1, 2016

Diagnosis method of active tuberculosis

Inventors: Edouard Tuaillon (Castelnau-le-Lez, FR); Pierre-Alain Rubbo (Montpellier, FR); Stephane Canaan (Marseilles, FR); Laurent Kremer (Montpellier, FR); Nicolas Nagot (Prades le Lez, FR); Philippe Van De Perre (Saint Vincent de Barbeyrargues, FR); Jean-Pierre Vendrell (Castelnau-le-Lez, FR)
Assignees: Universite Montpellier 2 Sciences et Technique; Universite Montpellier 1; Centre Hospitalier Universitaire de Montpellier; Centre National de La Recherche Scientifique
G01N33/5695
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,274,110
App. No.
14/123,699
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes.

Claims (36)

1. A method for the diagnosis of active tuberculosis, comprising:

a step of contacting a sample of purified B lymphocytes of a patient suspected to have an active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity and being able to hydrolyse lipids having a carbohydrate chain comprising at least 12 carbons selected from the group consisting of:

Rv3452 as set forth in SEQ ID NO: 1,

Rv1984c as set forth in SEQ ID NO: 2,

LipY, also called Rv3097c, as set forth in SEQ ID NO: 3,

Rv0183 as set forth in SEQ ID NO: 4,

PlcA, also called Rv2351c, as set forth in SEQ ID NO: 5,

PlcB, also called Rv2350c, as set forth in SEQ ID NO: 6,

PlcC, also called Rv2349c, as set forth in SEQ ID NO: 7, and

PlcD, as set forth in SEQ ID NO: 9 or SEQ ID NO: 8,

said sample being devoid of serum or of any fluid liable to contain soluble antibodies,

a step of incubation during a determined time to allow the purified B lymphocytes to secrete specific antibodies directed against said enzyme having a lipolytic activity, and

a step of detecting the presence of an immune complex comprising said antibodies and said enzyme having a lipolytic activity.

2. The method for the diagnosis of active tuberculosis according to claim 1 , wherein B lymphocytes are chosen among plasmablasts and plasmocytes.

3. The method for the diagnosis of active tuberculosis according to claim 1 , wherein the step of detecting the presence of activated B lymphocytes is carried out by an immunological detection.

4. The method for the diagnosis of active tuberculosis according to claim 1 , wherein said determined time is from 1 hour to 72 hours.

5. A kit for the detection of active tuberculosis comprising:

at least one protein of mycobacteria immobilised on a support, said protein being an enzyme having a lipolytic activity, selected from the group consisting of:

Rv3452 as set forth in SEQ ID NO: 1,

Rv1984c as set forth in SEQ ID NO: 2,

LipY, also called Rv3097c, as set forth in SEQ ID NO: 3,

Rv0183 as set forth in SEQ ID NO: 4,

PlcA, also called Rv2351c, as set forth in SEQ ID NO: 5,

PlcB, also called Rv2350c, as set forth in SEQ ID NO: 6,

PlcC, also called Rv2349c, as set forth in SEQ ID NO: 7, and

PlcD, as set forth in SEQ ID NO: 9 or SEQ ID NO: 8,

antibodies directed against constant chain of immunoglobulins, and

means for specifically purifying B lymphocytes.

6. The kit according to claim 5 , wherein said means specifically purifying B-lymphocytes are chosen among specific B cell specific antibodies, or density gradients, or a combination of the above.

7. The method for the diagnosis of active tuberculosis according to claim 1 , wherein said enzyme having a lipolytic activity is selected from the following enzymes:

Rv3452 as set forth in SEQ ID NO: 1,

Rv1984c as set forth in SEQ ID NO: 2, and

LipY as set forth in SEQ ID NO: 3.

8. The method for the diagnosis of active tuberculosis according to claim 1 , wherein said determined time is from 6 hours to 48 hours.

9. The method for the diagnosis of active tuberculosis according to claim 1 , wherein said determined time is from 16 h to 30 hours.

10. The kit according to claim 8 , wherein the antibodies are labelled.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 31, 2018
From: UNIVERSITE DE MONTPELLIER I; UNIVERSITE DE MONTPELLIER II; UNIVERSITE DE MONTPELLIER
To: UNIVERSITE DE MONTPELLIER
Reel/Frame 046517/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2014
From: TUAILLON, EDOUARD; RUBBO, PIERRE-ALAIN; CANAAN, STEPHANE; KREMER, LAURENT; NAGOT, NICOLAS; VAN DE PERRE, PHILLIPPE; VENDRELL, JEAN-PIERRE
To: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUE; UNIVERSITE MONTPELLIER 1; CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 032378/0297 →
Priority Claims (1)
EP 11168643 · Jun 3, 2011 · regional
Continuity (1)
Related Publication 20140220599A1 · Aug 7, 2014